source
- Novartis' RNA drug del-brax hits primary endpoint in early-stage FSHD trialNovartis reported that its antisense oligonucleotide conjugate, del-brax, achieved the primary biomarker endpoint in a Phase 1/2 study of patients with facioscapulohumeral muscular dystrophy (FSHD)…
- Novartis expands molecular glue program as Medicare drug spending surges and biotech firms report new data and fundingNovartis announced it is deepening its investment in molecular glue technology, a platform that aims to target previously undruggable proteins. The move signals the company’s confidence in the appr…